Repositioning Candidate Details
| Candidate ID: | R0643 |
| Source ID: | DB04901 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Galiximab |
| Synonyms: | Anti-CD80 monoclonal antibody; Galiximab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. |
| CAS Number: | 357613-77-5 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis. |
| DrugBank Pharmacology: | Galiximab is a monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Galiximab binds to the protein CD80, which is found on certain normal and cancerous white blood cells. |
| DrugBank MoA: | Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques. |
| Targets: | T-lymphocyte activation antigen CD80 antibody |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |